REDONDO BEACH, CA–(Marketwired – Jan 5, 2017) – SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces an article discussing the recent, successful completion of AXIM® Biotechnologies’ ( OTCQB : AXIM ) pharmacokinetic (PK) study of its CanChew Plus® CBD Gum. The single-dose study on 10 mg and 30 mg concentrations of cannabidiol (CBD) measured blood concentrations after chewing a single piece of gum for 30 minutes. The 30 mg dosage showed excellent bioavailability and will be used in the upcoming AX-1601 clinical trial.
The company will use the dosing data to determine the most optimal dosing for patients involved in its clinical trial, which will evaluate the safety and efficacy of CBD in treating the symptoms of Irritable Bowel Syndrome (IBS). In pre-clinical studies, CBD has been shown to modulate